Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.32 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5814754 | 1.00 | MAOB (0.35) | MAOBKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL5560604 | 0.93 | ABCB11 (0.33) | MAOBAKR1C3AKR1C2PTGS2MAPK1 | |
| SCHEMBL5560607 | 0.93 | ABCB11 (0.33) | MAOBAKR1C3AKR1C2PTGS2MAPK1 | |
| SCHEMBL5553638 | 0.91 | MEN1 (0.34) | MAOBKCNQ3KCNQ2AKR1C3AKR1C2 | |
| SCHEMBL5553642 | 0.91 | MEN1 (0.34) | MAOBKCNQ3KCNQ2AKR1C3AKR1C2 | |
| SCHEMBL5560060 | 0.90 | PTGS2 (0.39) | MAOBAKR1C3AKR1C2PTGS2SLC22A12 | |
| SCHEMBL5547164 | 0.90 | PTGS2 (0.39) | MAOBAKR1C3AKR1C2PTGS2SLC22A12 | |
| SCHEMBL5557078 | 0.90 | PTGS2 (0.39) | MAOBAKR1C3AKR1C2PTGS2SLC22A12 | |
| SCHEMBL5561117 | 0.90 | TRPV1 (0.34) | MAOBAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL5561120 | 0.90 | TRPV1 (0.34) | MAOBAKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006050120-A2 | SYNTHESIS OF COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | MAOB 181/4885KCNQ3 3015/4885KCNQ2 2615/4885 |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | MAOB 57/4885KCNQ3 4077/4885KCNQ2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.